Amdocs Limited NASDAQ: DOX

Fiscal Q2 2023 Earnings Presentation May 10, 2023

Shuky Sheffer President & CEO

Tamar Rapaport-Dagim CFO & COO



Disclaimer

The information contained herein in this presentation or delivered or to be delivered to you during this presentation does not constitute an offer, expressed or implied, or a recommendation to do any transaction in Amdocs Limited securities or in any securities of its affiliates or subsidiaries.

This presentation and the comments made by members of Amdocs management in conjunction with it include information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs' growth and business results in future quarters. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks and uncertainties that may cause future results to differ from those anticipated. These risks include, but are not limited to, the effects of general macro-economic conditions, prevailing level of macroeconomic, business and operational uncertainty, including as a result of geopolitical events or other global or regional events such as the COVID-19 pandemic, as well as the current inflationary environment, and the effects of these conditions on the company's clients' businesses and levels of business activity, Amdocs' ability to grow in the business markets that it serves, Amdocs' ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company's products and services obsolete, potential loss of a major customer, our ability to develop long-term relationships with our customers, and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, Amdocs' specifically disclaims any obligation to do so. These and other risks are discussed at greater length in Amdocs' filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2022 filed on December 13, 2022 and our Form 6-K furnished for the first quarter of fiscal 2023 on February 13, 2023.

This presentation includes non-GAAP financial measures, including non-GAAP operating margin, free cash flow, revenue on a constant currency basis, non-GAAP net income, non-GAAP net income attributable to Amdocs Limited, and non-GAAP earnings per share. Free cash flow equals cash generated by operating activities less net capital expenditures and other. While in prior years Amdocs used normalized free cash flow, a measure of our operating performance, is further adjusted to exclude net capital expenditures related to the new campus development, payments for non-recurring and unusual charges (such as capital gains tax to be paid in relation to the divestiture of OpenMarket), and payments of acquisition related liabilities, Amdocs is no longer reporting normalized free cash flow. Normalized free cash flow is not comparable to free cash flow. These non-GAAP financial measures are not in accordance with, or an alternative for, generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies. In addition, these non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles. Amdocs believes that non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with Amdocs' results of operations as determined in accordance with GAAP and that these measures should only be used to evaluate Amdocs' results of operations in conjunction with the corresponding GAAP measures. Please refer to the appendix for a reconciliation of these metrics to the most comparable GAAP provision.

This presentation also includes pro forma metrics which exclude the financial impact of OpenMarket (divested on December 31, 2020) from fiscal year 2021.

Please also review the information contained in Amdocs' press release dated May 10, 2023 with respect to earnings for fiscal Q2 2023. The press release contains additional information regarding Amdocs' outlook for fiscal year 2023 and certain non-GAAP metrics and their reconciliations.



Today's Speakers



Shuky Sheffer

President & Chief Executive Officer



Tamar Rapaport-Dagim

Chief Financial Officer & Chief Operating Officer





Earnings call agenda



Strategy & Business Performance Update

Shuky Sheffer, President & Chief Executive Officer

Financial Review & Outlook

Tamar Rapaport-Dagim, Chief Financial Officer & Chief Operating Officer








Shuky Sheffer

President & Chief Executive Officer

Strategy and Business Performance Update




Q2-23 solid quarter with significant achievements





Q2 financial highlights: Record revenue, continued sales momentum and ongoing margin improvement



1. Constant currency. Assumes exchange rates in the current period were unchanged from the prior period

2. Non-GAAP. See reconciliation tables in appendix


Information Security Level 0 – Public. © 2023 – Proprietary & Confidential Information of Amdocs



Q2-23 operational highlights



Strong execution



High rate of successful project deployment



Played an important role in the recent launch of fixed wireless access offering, 'Internet Air'

🗮 Strategy & offerings



CES

Strategic partnership to bring new Al-driven **Customer Engagement Platform**

Launched CES23, which includes enhanced capabilities designed to meet the complex demands of B2B

Entered agreement to acquire the service assurance business of TEOCO for ~\$90M

Enhance our network automation strategy by providing CSPs with end-to-end service orchestration offering



Progress in strategic domains (1/4)

Enable our customers to drive growth, improve cost-efficiency and provide an amazing experience to consumers and enterprises B2B customers

	Sele	ected wins	Business value
	PLDT Smart	End-to-end cloud migration services	Greater agility efficiency and scalability for business-critical systems
Cloud Sip			
Accelerate journey to the cloud	Tier 1 Central European operator	BSS transformation in multiple countries	Enable improved security, operability and resiliency while defining the journey towards a full cloud-native environment
	Major Western European operator	Expended managed services agreement for migration & operation of non-Amdocs applications	Enable operational agility, scalability, and ultimately, cloud at scale



Progress in strategic domains (2/4)


Enable our customers to drive growth, improve cost-efficiency and provide an amazing experience to consumers and enterprises B2B customers

	Selec	ted wins	Business value							
Digital transformation	Ŧ	Consumer and B2B digital transformation	Powerful insightful and transparent experiences across all channels							
Creating seamless	Major Eastern European operator	Customer engagement platform	Improved customer loyalty and retention							
digital experiences by transforming IT	Eastern European service provider	Digital transformation	Harmonized, frictionless customer experience across multiple channels and touchpoints							
operations for	YES	Premium user interface	Improved customer experience							
consumer and B2B customers	Amdocs eSIM ranke	ed number one eSIM orch	hestration platform by Counterpoint							
	Drei Austria	eSIM platform	Creating the next generation of frictionless experiences by offering eSIM-based connectivity							
10 Information Security Level 0 – Public @ 1	2023 - Proprietary & Confidential Information of A		make_it							

amazina


Progress in strategic domains (3/4)

Enable our customers to drive growth, improve cost-efficiency and provide an amazing experience to consumers and enterprises B2B customers



Progress in Strategic Domains (4/4)


Enable our customers to drive growth, improve cost-efficiency and provide an amazing experience to consumers and enterprises B2B customers





Looking Ahead: Reiterating FY2023 financial targets

While Amdocs and its customer globally are not immune to economic uncertainty and market dynamics, we believe in our unique business model which produces visible, high recurring revenue



1. Constant currency. Assumes exchange rates in the current period were unchanged from the prior period

2. Non-GAAP. See reconciliation tables in appendix

3. Earning to cash flow conversion.





Tamar Rapaport-Dagim

Chief Financial Officer & Chief Operating Officer

Financial Update & Outlook



Q2 FY2023 Financial Highlights

Record revenue, +6.8% YoY as reported and **+8.2% YoY** constant currency⁽¹⁾

Record quarter in North America

Record quarter in Europe

Improved non-GAAP operating margin, reflecting ongoing *efficiency* gains

Constant currency. Assumes exchange rates in the current period were unchanged from the prior period

2. Non-GAAP. See reconciliation tables in appendix

15

Information Security Level 0– Public© 2022 – Proprietary & Confidential Information of Amdocs

Q2 2023 Results

Q2 Revenue

\$1,223 million

+6.8% YoY, +8.2% constant currency⁽¹⁾ **Above** guidance midpoint **(\$1,200M - \$1,240M)**

Q2 Non-GAAP⁽²⁾ Operating Margin 17.8%, +20bps YoY

+10 bps QoQ and within annual target range of 17.5% - 18.1%


Q2 GAAP Diluted EPS **\$1.23**

Above midpoint of guidance (\$1.18 - \$1.26)

Q2 Non-GAAP⁽²⁾ Diluted EPS **\$1.47**

In line with guidance midpoint (\$1.44 - \$1.50)





Leading Indicators & Business Model Visibility

16

12-Month Backlog **1** B **Record-high** as of March 31, 2023 ~ +5.7% YoY, ~ +7% YoY cc **Leading Indicator** Roughly 80% 12-month backlog typically covers ~80% of

forward 12-month

revenue

Record Quarterly 12-Month Backlog in Q2F23 \$ Billions +\$20M QOQ \$4.11 \$4.09 \$3.97 \$3.95 +7% YoY cc \$3.89 +5.7% Yo \$3.83 Q2F22 Q1F22 Q3F22 Q4F22 Q1F23 Q2F23

12-month backlog includes:

- Anticipated revenue related to contracts
- Estimated revenue from **managed services** contracts
- Letters of intent
- Maintenance
- Estimated ongoing support activities



Leading Indicators & Business Model Visibility

17

Managed Services

Sest-ever Quarter ~ +8.4% YoY ~59% of total revenue


managed

services contract

renewals

Managed Services Revenue: Q2 2023 \$ Millions

Managed services arrangements support business model resiliency with highly recurring revenue streams, multi-year engagements and high renewal rates, and may also include large-scale digital transformation projects



Globe

Extended partnership to reimagine Globe's IT operations, enabled by digital transformation & cloud adaptation, for better business alignment under a multiyear managed services arrangement

Major Western European operator

Extended multi-year agreement to migrate and operate non-Amdocs applications to the cloud





.

Close to

100%

Balance Sheet & Cash Flow

DSO's 74 days


-7 days YoY and -13 days QoQ DSO's may fluctuate from quarter to quarter

Deferred revenue > unbilled +\$102 million QoQ

Deferred revenue: +\$88M QoQ Unbilled receivables: -\$14M QoQ

Items fluctuate from quarter to quarter in line with normal business activities.

Q2 2023 Free cash flow⁽²⁾ bridge



Healthy customer cash collections, offset by normal seasonal timing of annual bonus payments in Q2

1H FY2023 free cash flow **tracking in line** with annual target

Ample liquidity to support ongoing business needs while retaining the capacity to fund future strategic growth investments

\$650M senior note, maturing June 2030

Non-GAAP. See reconciliation tables in appendix

Liquidity: Cash + Credit Facility \$1.4 billion

Ample liquidity including available \$500M revolving credit facility





Remain committed to maintaining our Investment arade credit rating

Cash, Credit Facility & Debt Position

\$ Millions, as of March 31, 2023





Disciplined Capital Allocation

Reiterating free cash flow⁽¹⁾ (FCF) outlook of **\$700M** in FY2023, equating to roughly 100% cash conversion

~6% free cash flow yield⁽²⁾


Expects to return the **majority** of free cash flow to shareholders in FY2023

. Non-GAAP. See appendix tables for reconciliation of normalized FCF

19

- 2. Yield = expected reported free cash flow of \$700M in FY2023 as a percentage of Amdocs' market capitalization as of May 10, 2023
- 3. FCF in FY2020, FY2021 and FY2022 is presented on a normalized basis, which mainly excludes net capital expenditures related to the new campus development; normalized FCF disclosure is no longer applicable in FY2023
- 4. Refer to https://investors.amdocs.com/ and earnings reports issued on 11/2/2021 and 11/8/2022 for reconciliation of normalized FCF in FY2020, FY2021 and FY2022

Q2 2023 Cash Returned to Shareholders \$ Millions




Quarterly Dividend

Board authorized quarterly dividend payment:

43.5 cents

As of March 31, roughly **\$0.3B** of share repurchase authorization capacity remained

Normalized FCF ⁽¹⁾⁽³⁾⁽⁴⁾: Three-year historical trend and FY2023E outlook





FY2023 Outlook

FY2023E revenue growth outlook tightened to ~7%-9% YoY⁽⁴⁾, midpoint unchanged

Reiterating 9%-13% non-GAAP diluted EPS growth outlook

On-track to deliver **double-digit** expected total shareholder returns for **third** year running


 Pro forma metrics exclude the financial impact of OpenMarket (which was divested on December 31, 2020) from fiscal year 2021.

2. Non-GAAP. See reconciliation tables in appendix

20


- Expected total shareholder return assumes Non-GAAP EPS growth plus dividend yield (based on fiscal year end closing share price); FY2023E assumed 11% midpoint of pro forma non-GAAP EPS outlook, and dividend yield based on proposed new quarterly rate of \$0.435 as of share price on 11/8/22
- 4. Constant currency. Assumes exchange rates in the current period were unchanged from the prior period
- Refer to https://investors.amdocs.com/ and earnings reports issued on 11/10/2020, 11/2/2021 and 11/8/2022 for non-GAAP reconciliation in FY2019, FY2020, FY2021 and FY2022
 - Information Security Level 0– Public© 2022 Proprietary & Confidential Information of Amdocs

Revenue Growth YoY% Growth Constant Currency⁽⁴⁾ FY21 and FY22 revenue is pro forma⁽¹⁾ constant currency⁽⁴⁾




Total Shareholder Return⁽³⁾⁽⁵⁾

Non-GAAP⁽²⁾ Diluted EPS Growth YoY % + Dividend Yield FY21 and FY22 non-GAAP EPS growth is presented pro forma⁽¹⁾



*Non-GAAP⁽²⁾ EPS growth of 11%, plus ~2% dividend yield





Completed the move to the new Amdocs Park campus in March



Raised ~\$100,000 to **support earthquake recovery in Turkey** in an employee donation drive with Unicef





Let's make it amazing



Q3 & FY2023 Outlook

On-track to deliver **doubledigit** total shareholder returns for the **third** year running

1. Non-GAAP. See reconciliation tables in appendix

2. Constant currency. Assumes exchange rates in the current period were unchanged from the prior period

Q3 Fiscal 2023 Outlook

Revenue	\$1	1,215 - \$1,255 million						
GAAP EPS	\$1	\$1.16 - \$1.26						
Non-GAAP ⁽¹⁾ EPS	\$1	1.45 - \$1.51						
Share Count	12	21 million						
Non-GAAP ⁽¹⁾ Effective Tax Rate		line with annual target inge of 13%-17%						
Full Year Fiscal 2023 Outlook	Updated	Previous						
Revenue growth As reported	6.0% - 8.0%	5.0% - 9.0%						
Revenue growth Constant currency ⁽²⁾	7.0% - 9.0%	6.0% - 10.0%						
GAAP EPS growth	3.0% - 10.0%	3.0% - 10.0%						
Non-GAAP ⁽¹⁾ EPS growth	9.0% - 13.0%	9.0% - 13.0%						
Non-GAAP ⁽¹⁾ Operating Margin	17.5% - 18.1%	17.5% -18.1%						
Non-GAAP ⁽¹⁾ Effective Tax Rate	13.0% - 17.0%	13.0% -17.0%						
Free cash flow ⁽¹⁾	\$700 million	\$700 million						



Appendix

Reconciliation Tables



Reconciliation Tables

- (a) The amounts under "Purchase of property and equipment, net" include proceeds from sale of property and equipmentof \$255 and \$555 for the six months ended March 31, 2023 and 2022, respectively.
- (b) Since Q12023, the Normalized Free Cash Flow is no longer applicable.

		2023	_	2022
Revenue	S	1,223,304	\$	1,145,271
Non-GAAP operating income		217,737		201,625
Non-GAAP net income		179,298		190,944
Non-GAAP net income attributable to Amdocs Limited		178,592		190,944
Non-GAAP diluted earnings per share	\$	1.47	\$	1.54
Diluted weighted average number of shares outstanding		121,359		123,821
	Fre	e Cash Flo	ws	

(In thousands) Three months ended Six months ended March 31, March 31, 2023 2022 2023 2022 Net Cash Provided by Operating Activities 294.476 \$ 168,856 \$ 377.702 \$ 372.974 s Purchases of property and equipment, net (a) (35, 119)(47,271) (68,822) (104,496) Free Cash Flow S 259.357 \$ 121,585 \$ 308,880 \$ 268,478

AMDOCS LIMITED Selected Financial Metrics (In thousands, except per share data)

Three months ended

March 31.

Normalized Free Cash Flow ^(b) for the three and six months ended March 31, 2022: \$159,758 and \$345,437, respectively, excluding net capital expenditures related to the new campus development of \$30,109 and \$59,416, respectively, payment for acquisition related liability of \$4,871 and \$14,350, respectively, and tax payment on sale of business of \$3,193.



Six months ended

March 31,

2,409,024 \$

427,275

355.840

354.929

121.430

2.92 \$

2022

2.249.903

395,232

341.079

341.079

124.571

2.74

2023

S

S

AMDOCS LIMITED Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP (In thousands)

Reconciliation	
Tables	

			Th	ree	Months Ended	Mar	ch 31, 2023			
	GAAP	of pu inta ass	rtization Irchased angible ets and other		Equity based ompensation expense	a j m	Changes in certain cquisitions related liabilities leasured at fair value	Tax effect	N	Jon-GAAP
Operating expenses:										
Cost of revenue	\$ 795,485	\$	-	\$	(10,061)	\$	(1,159)	\$ -	\$	784,265
Research and development	89,274				(1,703)					87,571
Selling, general and administrative	143,328				(9,597)					133,731
Amortization of purchased intangible assets and other	12,940		(12,940)							-
Total operating expenses	1,041,027		(12,940)		(21,361)		(1,159)	-		1,005,567
Operating income	182,277		12,940		21,361		1,159	 -		217,737
Interest and other expense, net	(2,938)									(2,938)
Income taxes	29,030							6,471		35,501
Net income	150,309		12,940		21,361		1,159	(6,471)	179,298
Net income attributable to noncontrolling interests	706									706
Net income attributable to Amdocs Limited	\$ 149,603	\$	12,940	\$	21,361	\$	1,159	\$ (6,471)\$	178,592

						Three Mon	th	s Ended March 3	31, 2022			
Occupations and accurate		GAAP	of i	nortization purchased ntangible issets and other		Equity based compensation expense	ł	Changes in certain acquisitions related liabilities neasured at fair value	Other		Tax effect	Non-GAAP
Operating expenses: Cost of revenue	¢	741.257	¢		\$	(8,070)	¢	(1,820) \$		s	- \$	731.367
Research and development	9	87,064	9		9	(1,375)		(1,820) \$	-	9		85,689
Selling, general and administrative		134,982				(8,392)						126,590
Amortization of purchased intangible												
assets and other		18,317		(18,317)								-
Total operating expenses		981,620		(18,317)		(17,837)		(1,820)	-		-	943,646
Operating income		163,651	_	18,317		17,837		1,820	-		-	201,625
Interest and other expense, net		(8,619)							1,100			(7,519)
Income tax (benefit) expense		(3,465)			_		_				6,627	3,162
Net income	\$	158,497	\$	18,317	\$	17,837	\$	1,820 \$	1,100	\$	(6,627) \$	190,944



AMDOCS LIMITED Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP (In thousands)

Reconci	liatio	n
Tables		

						Six Mont	hs	Ended March	h 3	1, 2023				
		GAAP	of p in as	ortization ourchased tangible sets and other		Equity based compensation expense	a	Changes in certain acquisitions related liabilities neasured at fair value	R	estructuring charges		Tax effect	I	Non-GAAP
Operating expenses:							_							
Cost of revenue	\$	1,552,334	\$	-	\$	(18,716)	\$	(1,284))\$	-	\$	- 1	\$	1,532,334
Research and development		185,000				(3,187)								181,813
Selling, general and administrative		286,550				(18,948)								267,602
Amortization of purchased intangible														
assets and other		28,253		(28,253)										-
Restructuring charges		24,536								(24,536)				-
Total operating expenses		2,076,673		(28,253)		(40,851)		(1,284))	(24,536)		-		1,981,749
Operating income		332,351		28,253		40,851		1,284		24,536		-		427,275
Interest and other expense, net		(7,901))											(7,901)
Income taxes		44,269										19,265		63,534
Net income		280,181		28,253		40,851	_	1,284		24,536		(19,265)		355,840
Net income attributable to noncontrolling	ξ				_		_		_		_			
interests	-	911												911
Net income attributable to Amdocs	_													
Limited	\$	279,270	\$	28,253	\$	40,851	\$	1,284	\$	24,536	\$	(19,265)	\$	354,929

	_					Circ Manutha	E		21	2022			 	
						Six Months	-	nded March	31	, 2022				
							C	hanges in						
								certain						
				mortization			a	cquisitions						
				f purchased	-			related	_					
				intangible		Equity based		liabilities		ain from			т	
		GAAP		assets and	c	ompensation		easured at		sale of a	Oth		Tax effect	Non-
0 5		GAAP	_	other	_	expense		fair value	_	business	Oth	er	 enect	GAAP
Operating expenses:														
Cost of revenue	\$	1,457,975	\$	-	\$	(15,217)	\$	(793)	\$	- \$		-	\$ -	\$ 1,441,965
Research and development		169,009				(2,598)								166,411
Selling, general and administrative		263,058				(16,763)								246,295
Amortization of purchased intangible														
assets and other		36,064		(36,064)										-
Total operating expenses		1,926,106		(36,064)		(34,578)		(793)		-		-	-	1,854,671
Operating income		323,797		36,064	_	34,578		793		-		-	 -	395,232
Interest and other expense, net		(11,181)									(2,505)		(13,686)
Gain from sale of a business		10,000							\$	(10,000)				-
Income tax (benefit) expense		30,517											9,950	40,467
Net income	\$	292,099	\$	36,064	\$	34,578	\$	793	\$	(10,000) \$	(2,505)	\$ (9,950)	341,079



Let's make it amazing

